BIOGEN INC.: retained earnings or deficit
Retained earnings or deficit for BIOGEN INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All BIOGEN INC. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2008-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 20,552,700,000 | USD | 2026-02-06 | 10-K · 0000875045-26-000013 |
| At date | 2024-12-31 | 19,259,800,000 | USD | 2026-02-06 | 10-K · 0000875045-26-000013 |
| At date | 2023-12-31 | 17,627,600,000 | USD | 2025-02-12 | 10-K · 0000875045-25-000009 |
| At date | 2022-12-31 | 16,466,500,000 | USD | 2024-02-14 | 10-K · 0000875045-24-000009 |
| At date | 2021-12-31 | 13,911,700,000 | USD | 2023-02-15 | 10-K · 0000875045-23-000009 |
| At date | 2020-12-31 | 13,976,300,000 | USD | 2022-02-03 | 10-K · 0000875045-22-000007 |
| At date | 2019-12-31 | 16,455,400,000 | USD | 2021-02-03 | 10-K · 0000875045-21-000010 |
| At date | 2018-12-31 | 16,257,000,000 | USD | 2020-02-06 | 10-K · 0000875045-20-000005 |
| At date | 2017-12-31 | 15,810,400,000 | USD | 2019-02-06 | 10-K · 0000875045-19-000006 |
| At date | 2016-12-31 | 15,071,600,000 | USD | 2018-02-01 | 10-K · 0000875045-18-000005 |
| At date | 2015-12-31 | 12,208,400,000 | USD | 2017-02-02 | 10-K · 0000875045-17-000009 |
| At date | 2014-12-31 | 9,283,900,000 | USD | 2016-02-03 | 10-K · 0000875045-16-000042 |
| At date | 2013-12-31 | 6,349,135,000 | USD | 2015-02-04 | 10-K · 0000875045-15-000005 |
| At date | 2012-12-31 | 4,486,794,000 | USD | 2014-02-06 | 10-K · 0000875045-14-000004 |
| At date | 2011-12-31 | 3,106,761,000 | USD | 2013-02-05 | 10-K · 0000875045-13-000006 |
| At date | 2010-12-31 | 1,872,481,000 | USD | 2012-02-03 | 10-K · 0001193125-12-039072 |
| At date | 2009-12-31 | 1,068,890,000 | USD | 2011-02-04 | 10-K · 0000950123-11-009300 |
| At date | 2008-12-31 | 270,180,000 | USD | 2010-02-09 | 10-K · 0000950123-10-010528 |
Related financial histories
- BIOGEN INC.: total assets
- BIOGEN INC.: total liabilities
- BIOGEN INC.: stockholders equity
- BIOGEN INC.: cash and cash equivalents
- BIOGEN INC.: net income or loss
- BIOGEN INC.: operating cash flow
- BIOGEN INC.: capital expenditure payments
- BIOGEN INC.: revenue
- BIOGEN INC.: financing cash flow
- BIOGEN INC.: investing cash flow
- BIOGEN INC.: basic weighted-average shares
- BIOGEN INC.: diluted weighted-average shares
- BIOGEN INC.: basic earnings per share
- BIOGEN INC.: diluted earnings per share
- BIOGEN INC.: income tax expense or benefit
- BIOGEN INC.: net property, plant and equipment
- BIOGEN INC.: share-based compensation expense
- BIOGEN INC.: operating income or loss
- BIOGEN INC.: current assets
- BIOGEN INC.: interest expense
- BIOGEN INC.: current liabilities
- BIOGEN INC.: current accounts payable
- BIOGEN INC.: goodwill carrying amount
- BIOGEN INC.: net finite-lived intangible assets
- BIOGEN INC.: net current accounts receivable
- BIOGEN INC.: common-stock repurchase payments
- BIOGEN INC.: net inventory
- BIOGEN INC.: gross profit
- BIOGEN INC.: cost of revenue
- BIOGEN INC.: selling, general and administrative expense
- BIOGEN INC.: research and development expense
Inspect the source
- Entity
- BIOGEN INC. / CIK 0000875045
- Captured
- 2026-09-20T05:00:52.520Z
- SEC response SHA-256
e49b5a3bbf14de0fb7d239cc7824bd2fd0df6e7d76ccea2ef08421f0f26763e0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000875045.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))